Sahm Adrangi is a hedge funder who is primarily known for short selling and publishing research. In 2009 the businessman and entrepreneur founded Kerrisdale Capital Management, a research oriented investment firm. He also serves as the firm’s Chief Investment Officer. Overall, as founder and CIO Adrangi is takes a very hands on approach to running the firm. He is heavily involved in every major decision and direction of the firm’s development. Under the leadership of Adrangi the firm has grown form a company founded with less than $1 million to one that now manages more than $150 million.
Early in his career Sahm Adrangi garnered attention by exposing Chinese companies for shady business practices. Some of the more notable companies he exposed include China Marine Food Group and Lihua International. Because of Adrangi’s efforts many of these companies were targeted by the Securities and Exchange Commission.
Although Sahm Adrangi and Kerrisdale Capital do not discriminate against which companies they research the hedge funder has made companies in the biotech industry an important area of focus lately. This could be because Kerrisdale recently developed an expertise in the biotech sector. He has called out several companies for fraudulent behavior and is usually right.
Sahm Adrangi recently led a brutal attack against biotech company Prothena. He blasted the company by strongly predicting its lead drug would be a failure. The drug in question was NEOD001, an AL amyloidosis drug. And as usual he was spot on. The drug underperformed in trials and was written off by Prothena.
One things for sure is that Adrangi takes no prisoners. When he sets his sights on a target he is both brutal and relentless. He single-handedly has every comapny in the biotech sector on their Ps and Qs. This is why he is one of the most influential hi=edge funders in the nation.
His Twitter Profile: https://twitter.com/sahmadrangi